Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Gross Profit (2020 - 2025)

Maxcyte (MXCT) has disclosed Gross Profit for 6 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 11.26% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.8 million through Dec 2025, down 14.98% year-over-year, with the annual reading at $26.8 million for FY2025, 14.98% down from the prior year.
  • Gross Profit for Q4 2025 was $5.7 million at Maxcyte, up from $5.2 million in the prior quarter.
  • The five-year high for Gross Profit was $14.1 million in Q4 2023, with the low at $5.2 million in Q3 2025.
  • Average Gross Profit over 5 years is $8.2 million, with a median of $8.1 million recorded in 2022.
  • The sharpest move saw Gross Profit soared 81.4% in 2022, then tumbled 54.5% in 2024.
  • Over 5 years, Gross Profit stood at $8.9 million in 2021, then rose by 21.86% to $10.9 million in 2022, then grew by 29.56% to $14.1 million in 2023, then crashed by 54.5% to $6.4 million in 2024, then fell by 11.26% to $5.7 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $5.7 million, $5.2 million, and $7.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.